Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + anlotinib + chemotherapy for first-line recurrent/metastatic head and neck squamous cell carcinoma
ChiCTR2300068672Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Sanhuan Cancer Hospital
- Start
- Oct 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zimberelimab, anlotinib, paclitaxel, cisplatin and carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Beijing Chaoyang Sanhuan Cancer Hospital. Primary endpoint: Overall response rate. Started Oct 2022; status: recruiting.
02
Drugs
zimberelimabanlotinibpaclitaxelcisplatincarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2300068672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068672.